Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Sanford J. Shattil Clear advanced filters

  • Members of the integrin family of receptors, which are involved in cell–cell adhesion, have been successfully targeted for cardiovascular disease, multiple sclerosis and inflammatory bowel disease. Ley and colleagues review the biological basis for the development of the next generation of integrin-targeted drugs, highlighting lessons learned from successes and failures.

    • Klaus Ley
    • Jesus Rivera-Nieves
    • Sanford Shattil
    Reviews
    Nature Reviews Drug Discovery
    Volume: 15, P: 173-183

  • Integrin activation comprises initial and intermediate signalling events and, finally, the interaction of integrins with cytoplasmic regulators such as talins and kindlins, which changes an integrin's affinity for its ligands. Targeting of these final, integrin-specific, activation events enables integrin-focused therapeutic strategies.

    • Sanford J. Shattil
    • Chungho Kim
    • Mark H. Ginsberg
    Reviews
    Nature Reviews Molecular Cell Biology
    Volume: 11, P: 288-300

  • Most receptors transmit extracellular signals to the cytoplasm, but integrins can also be stimulated in the reverse direction. A recent pair of Science papers report that “inside-out” signaling from the TCR is mediated by a newly identified protein called SLAP-130 or Fyb.

    • Darren G. Woodside
    • Sanford J. Shattil
    • Mark H. Ginsberg
    News & Views
    Nature Immunology
    Volume: 2, P: 904-905